Kelso Group Holdings PLC
LLSE:KLSO3.50
GBX
0.00
(0.00%)
Kelso Group Holdings PLC
LSE:KLSO
(London Stock Exchange)
Recent
price
3.50
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
GBP
•
in mil. unless spec.Working Capital
GBP
•
in mil. unless spec.Growth Rates
GBP
•
in mil. unless spec.Semi-annual Revenue
GBP
•
in mil. unless spec.Semi-annual Earnings Per Share
GBP
•
in mil. unless spec.Semi-annual Dividends Per Share
GBP
•
in mil. unless spec.- Similar Companies
- Business
- Kelso Group Holdings Plc operates as a United Kingdom-based investment holding company focused on identifying, engaging, and unlocking value primarily in UK small and mid-cap public markets through its subsidiary Kelso Ltd. The company's core business involves investing in undervalued securities where there is a significant disparity between intrinsic value and stock market valuation. Kelso's investment approach centers on acquiring stakes in companies with growth potential, then partnering with their management teams to create value. The firm operates chiefly within the UK market and targets sectors across diverse industries, with active engagement in investment and trading activities. In terms of recent major changes, Kelso Group Holdings Plc completed the sale of one of its significant portfolio entities, Accession Management Group, to Brown & Brown Inc. in a transaction valued at approximately $9.83 billion in 2025. Under Kelso’s ownership, Accession expanded both organically and through more than 180 acquisitions, growing revenue from $130 million to $1.7 billion and employee numbers from 500 to 5,500. This divestment represents one of the largest private equity exits in insurance brokerage, marking a strategic shift as Kelso monetizes a matured investment. Further, Kelso Pharma, a specialty pharmaceutical business supported by Apposite Capital, acquired the UK pharmaceutical firm ALTURiX in early 2025 to build scale and expand its branded specialty medicine offerings in the UK and Europe. This acquisition aligns with Kelso’s strategy of growing specialized portfolio businesses. Kelso Group Holdings was incorporated in 2018 and is headquartered in London. It operates primarily as an investment company through Kelso Ltd, which focuses on value creation within smaller UK public companies. The company also benefits from strategic partnerships and funding rounds to support its portfolio expansions, exemplified by Kelso Pharma’s recent funding and executive appointments aimed at bolstering its specialty pharmaceutical segment. Kelso’s investment targets typically include small and mid-cap companies poised for operational improvements and market re-rating. Overall, Kelso Group Holdings Plc concentrates on investment management and value investing with diversified holdings across sectors and selective strategic acquisitions, supported by a London headquarters and a foundation in public market investment since 2018. This description reflects Kelso Group Holdings Plc’s investment activities, portfolio growth, recent major disposals, and acquisitions up to late 2025.